Violi Francesco, Cangemi Roberto
IV Divisione di Clinica Medica, Viale del Policlinico 155, Roma 00161, Italy.
Curr Opin Investig Drugs. 2005 Sep;6(9):895-900.
Oxidative stress appears to play a key role in the pathogenesis of atherosclerosis. Agents that prevent the oxidation of low-density lipoprotein have reduced the development and progression of this disease in a range of in vitro experiments and animal models. In the last decade, many trials of antioxidants in patients with cardiovascular disease have been conducted, but the results have been ambiguous. The reason for the disappointing findings is unclear, but one possible explanation is the lack of identification criteria for patients who are potential candidates for antioxidant treatment. This review analyzes data reported to date, in order to determine whether these clearly support the premise that patients at risk of cardiovascular disease may be candidates for this therapeutic option.
氧化应激似乎在动脉粥样硬化的发病机制中起关键作用。在一系列体外实验和动物模型中,能够防止低密度脂蛋白氧化的药物已减缓了这种疾病的发展和进程。在过去十年中,已经对心血管疾病患者进行了许多抗氧化剂试验,但结果并不明确。结果令人失望的原因尚不清楚,但一种可能的解释是缺乏对抗氧化治疗潜在候选患者的识别标准。这篇综述分析了迄今为止报告的数据,以确定这些数据是否明确支持心血管疾病风险患者可能是这种治疗选择候选者的前提。